← Eichor
Condition: Tolerability Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Tolerability

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT06687070Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 for Treating ARDS
Phase 1 · 2 location(s) · HTIC, Inc · NCT07449572A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older
Phase 3 · 174 location(s) · Pfizer · NCT07282665Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05126472Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight
Phase 1 · 1 location(s) · Suzhou Alphamab Co., Ltd. · NCT06547775Clinical Trial of TQB3205 Capsule in Subjects With Advanced Malignant Tumors
Phase 1 · 1 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07482592A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fractio
Phase 1 · 21 location(s) · Vasa Therapeutics · NCT07219511Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 · 29 location(s) · Novartis Pharmaceuticals · NCT06562192A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Phase 2 · 20 location(s) · Takeda · NCT06798012A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
Phase 2 · 70 location(s) · Intra-Cellular Therapies, Inc. · NCT06651567To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Health
Phase 1 · 1 location(s) · Shenzhen Kexing Pharmaceutical Co., Ltd. · NCT07237464A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults
Phase 1 · 1 location(s) · Vaxcyte, Inc. · NCT07616934Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Phase 2 · 6 location(s) · Omeros Corporation · NCT06209736A Study of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases
EARLY_Phase 1 · 5 location(s) · Nanjing Legend Biotech Co. · NCT07095075Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute
Phase 2 · 11 location(s) · ReAlta Life Sciences, Inc. · NCT06343792A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism
Phase 3 · 3 location(s) · Ascendis Pharma A/S · NCT07706764A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administ
Phase 1/Phase 2 · 8 location(s) · SNIPR Biome Aps. · NCT06938867A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Pr
Phase 4 · 2 location(s) · Sanofi · NCT06145373A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Phase 1 · 19 location(s) · Merck Sharp & Dohme LLC · NCT07247110A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injectio
Phase 1 · 65 location(s) · GlaxoSmithKline · NCT06431594The DART DELIVER-02 Study
Phase 1 · 3 location(s) · University of North Carolina, Chapel Hill · NCT07217379TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Phase 1 · 2 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06088888Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subje
Phase 2 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07175220A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
Phase 1/Phase 2 · 1 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT05991583Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepato
Phase 2 · 4 location(s) · Riboscience, LLC. · NCT07175441Inhaled RB042 in Healthy Adult Volunteers and Healthy Adult Smokers
Phase 1 · 1 location(s) · Atisama Therapeutics · NCT07285122A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Vibrant Sciences Limited · NCT07222969
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.